Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VIYASH.NS
Strong BuyPremium GrowerViyash Scientific Limited · Healthcare · India · $1.2B · Avg Vol: $20M/d
88
StockRankGet insider-trade alerts
Q
68
V
33
M
86
P/E (TTM)
55.3x
ROE
6.1%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.2B | 13.7B | 29.6B | 33.6B | 33.3% | 35.8B | 38.3B | 43.9B | 14.3% |
| EPS (INR) | -4.88 | -1.44 | 0.54 | 4.09 | 657.4% | 4.74 | 7.38 | — | 80.5% |
| Shares | 249.4M | 249.0M | 249.9M | 436.4M | +75.0% | 440.1M | — | — | — |
| Debt | 4.4B | 4.9B | 6.5B | 4.9B | 3.4% | 4.9B | — | — | — |
| Equity | 7.0B | 6.6B | 24.3B | 29.1B | 60.9% | — | — | — | — |
| Op CF | 168.1M | 305.9M | 3.4B | 3.2B | 167.8% | 3.2B | — | — | — |
| Inv CF | -649.6M | -59.2M | -4.5B | -841.2M | — | — | — | — | — |
| Fin CF | 322.3M | -14.4M | 870.4M | -1.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+4.0%
SMA 50SMA 200
Close
$2.75
RSI (14)
46.9
52W High
$3.13
From 52W High
0.9%
SCORE BREAKDOWN
Quality
68
ROIC
10.7%73.0
ROE
6.1%58.0
GP/Assets
40.4%78.0
Op. Margin
12.5%68.9
FCF/Assets
4.1%65.7
Piotroski
894.2
Int. Cover
6.9x55.9
D/E Ratio
0.16x54.6
Current Ratio
2.38x46.3
Value
33
P/E (TTM)
55.3x19.7
EV/EBITDA
17.4x40.6
P/FCF
61.4x24.8
P/B
3.9x36.9
P/S
3.2x54.5
Div Yield
—N/A
Momentum
86
52W High %
88%80.3
RS 6M
38%88.0
SMA 50/200
1.16x84.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+146%82.4
Q Growth
360%95.9
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
22.5x
Gross Margin
52.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VIYASH.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VIYASH.NS | Viyash Scientific Limited(you) | $1.2B | 88 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%